In Stockholm, the clinical guidelines changed in 2022 and global Ki67 has been incorporated together with grade, tumor size, ER/PR/HER2 status in the decision-making on molecular profiling test and or on adjuvant chemotherapy. This evidence concerns the gene ESR1 and neoplasm.